ALK 在肺癌中的过去、现在和未来。
ALK in lung cancer: past, present, and future.
机构信息
Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA.
出版信息
J Clin Oncol. 2013 Mar 10;31(8):1105-11. doi: 10.1200/JCO.2012.44.5353. Epub 2013 Feb 11.
Abstract
In 2007, scientists discovered that anaplastic lymphoma kinase (ALK) gene rearrangements are present in a small subset of non-small-cell lung cancers. ALK-positive cancers are highly sensitive to small-molecule ALK kinase inhibitors, such as crizotinib. Phase I and II studies of crizotinib in ALK-positive lung cancer demonstrated impressive activity and clinical benefit, leading to rapid US Food and Drug Administration approval in 2011. Although crizotinib induces remissions and extends the lives of patients, cures are not achieved as resistance to therapy develops. In this review, we will discuss the history of this field, current diagnostic and treatment practices, and future challenges and opportunities to advance outcomes for patients with ALK-positive lung cancers.
摘要
2007 年，科学家发现间变性淋巴瘤激酶（ALK）基因重排在一小部分非小细胞肺癌中存在。ALK 阳性癌症对小分子 ALK 激酶抑制剂如克唑替尼非常敏感。ALK 阳性肺癌的克唑替尼的 I 期和 II 期研究显示出令人印象深刻的活性和临床获益，导致 2011 年迅速获得美国食品和药物管理局的批准。尽管克唑替尼诱导缓解并延长了患者的生命，但由于对治疗的耐药性的出现，并没有实现治愈。在这篇综述中，我们将讨论这一领域的历史、当前的诊断和治疗实践，以及未来为 ALK 阳性肺癌患者改善预后的挑战和机遇。
相似文献
1
ALK in lung cancer: past, present, and future.ALK 在肺癌中的过去、现在和未来。
J Clin Oncol. 2013 Mar 10;31(8):1105-11. doi: 10.1200/JCO.2012.44.5353. Epub 2013 Feb 11.
2
Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies.ALK重排的晚期非小细胞肺癌（NSCLC）对克唑替尼的耐药性：机制、治疗策略及新的靶向治疗方法
Curr Clin Pharmacol. 2016;11(2):77-87. doi: 10.2174/1574884711666160502124134.
3
Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond.克唑替尼：一种新型的、同类首创的多靶点酪氨酸激酶抑制剂，用于治疗间变性淋巴瘤激酶重排的非小细胞肺癌及其他疾病。
Drug Des Devel Ther. 2011;5:471-85. doi: 10.2147/DDDT.S19045. Epub 2011 Nov 23.
4
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.克唑替尼治疗携带 ALK 基因重排的晚期非小细胞肺癌患者的总生存影响：一项回顾性分析。
Lancet Oncol. 2011 Oct;12(11):1004-12. doi: 10.1016/S1470-2045(11)70232-7. Epub 2011 Sep 18.
5
ALK inhibitors in the treatment of advanced NSCLC.ALK 抑制剂治疗晚期 NSCLC。
Cancer Treat Rev. 2014 Mar;40(2):300-6. doi: 10.1016/j.ctrv.2013.07.002. Epub 2013 Aug 7.
6
Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: Recent Progress and Future Directions.ALK 重排非小细胞肺癌的治疗：最新进展与未来方向。
Drugs. 2015 Jul;75(10):1059-70. doi: 10.1007/s40265-015-0415-9.
7
New strategies for treatment of ALK-rearranged non-small cell lung cancers.针对 ALK 重排非小细胞肺癌的新治疗策略。
Clin Cancer Res. 2011 Dec 1;17(23):7213-8. doi: 10.1158/1078-0432.CCR-11-1404. Epub 2011 Oct 18.
8
Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer.双重 ALK 和 EGFR 抑制靶向治疗针对 ALK 重排肺癌对酪氨酸激酶抑制剂克唑替尼获得性耐药的机制。
Lung Cancer. 2014 Jan;83(1):37-43. doi: 10.1016/j.lungcan.2013.09.019. Epub 2013 Oct 14.
9
Detection of anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer and related issues in ALK inhibitor therapy: a literature review.检测非小细胞肺癌中的间变性淋巴瘤激酶 (ALK) 基因重排及 ALK 抑制剂治疗中的相关问题：文献综述。
Mol Diagn Ther. 2012 Jun 1;16(3):143-50. doi: 10.1007/BF03262202.
10
ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC.ALK 抑制剂：晚期 NSCLC 治疗的一种新的靶向治疗方法。
Target Oncol. 2013 Mar;8(1):55-67. doi: 10.1007/s11523-012-0250-9. Epub 2013 Jan 17.
引用本文的文献
1
Diagnostic accuracy of circulating tumor DNA for detection of ALK rearrangement in lung cancer: A systematic review and meta-analysis of 14 studies.循环肿瘤DNA检测肺癌中ALK重排的诊断准确性：14项研究的系统评价和荟萃分析
PLoS One. 2025 Aug 25;20(8):e0330855. doi: 10.1371/journal.pone.0330855. eCollection 2025.
2
Lung Adenocarcinoma Expressing an EML4-ALK Fusion Transcript With Premature Stop Codons and Response to Alectinib: A Case Report.表达带有提前终止密码子的EML4-ALK融合转录本的肺腺癌及对阿来替尼的反应：一例报告
Thorac Cancer. 2025 Aug;16(15):e70146. doi: 10.1111/1759-7714.70146.
3
Fusion genes in cancers: Biogenesis, functions, and therapeutic implications.癌症中的融合基因：生物发生、功能及治疗意义
Genes Dis. 2025 Jan 20;12(5):101536. doi: 10.1016/j.gendis.2025.101536. eCollection 2025 Sep.
4
Design, synthesis and antitumor activity of thiadiazole derivatives as novel ALK kinase inhibitors.噻二唑衍生物作为新型ALK激酶抑制剂的设计、合成及抗肿瘤活性
Mol Divers. 2025 Jun 22. doi: 10.1007/s11030-025-11259-7.
5
Advances in molecular pathology and therapy of non-small cell lung cancer.非小细胞肺癌分子病理学与治疗的进展
Signal Transduct Target Ther. 2025 Jun 15;10(1):186. doi: 10.1038/s41392-025-02243-6.
6
Delayed Bronchopleural Fistula Formation Following Salvage Surgery of Stage IV Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.间变性淋巴瘤激酶阳性非小细胞肺癌IV期挽救性手术后迟发性支气管胸膜瘘的形成
Curr Oncol. 2025 Apr 25;32(5):250. doi: 10.3390/curroncol32050250.
7
Safety Profile and Hepatotoxicity of Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: A Disproportionality Analysis Based on FDA Adverse Event Reporting System Database.间变性淋巴瘤激酶酪氨酸激酶抑制剂的安全性和肝毒性：基于美国食品药品监督管理局不良事件报告系统数据库的不成比例性分析
Toxics. 2025 Mar 14;13(3):210. doi: 10.3390/toxics13030210.
8
A novel automated IHC staining system for quality control application in ALK immunohistochemistry testing.一种用于ALK免疫组化检测质量控制应用的新型自动化免疫组化染色系统。
Pathol Oncol Res. 2025 Feb 13;31:1611964. doi: 10.3389/pore.2025.1611964. eCollection 2025.
9
Real-World Incidence of Anaplastic Lymphoma Kinase Alterations in Hispanics with Non-Small Cell Lung Cancer at a Large Academic Institution in Los Angeles.洛杉矶一家大型学术机构中西班牙裔非小细胞肺癌患者间变性淋巴瘤激酶改变的真实世界发病率
Cancer Res Commun. 2025 Feb 1;5(2):277-286. doi: 10.1158/2767-9764.CRC-24-0504.
10
Sex differences in patients with Non-Small Cell Lung Cancer harboring driver fusions treated with tyrosine kinase inhibitors: a systematic review.携带驱动融合基因的非小细胞肺癌患者接受酪氨酸激酶抑制剂治疗的性别差异：一项系统综述
Ther Adv Med Oncol. 2024 Dec 17;16:17588359241306940. doi: 10.1177/17588359241306940. eCollection 2024.
本文引用的文献
1
Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer.培美曲塞为基础的化疗用于晚期 ALK 阳性非小细胞肺癌患者。
Ann Oncol. 2013 Jan;24(1):59-66. doi: 10.1093/annonc/mds242. Epub 2012 Aug 10.
2
KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only.KLC1-ALK：一种仅使用福尔马林固定石蜡包埋组织即可鉴定的肺癌新型融合基因。
PLoS One. 2012;7(2):e31323. doi: 10.1371/journal.pone.0031323. Epub 2012 Feb 8.
3
Escaping ALK inhibition: mechanisms of and strategies to overcome resistance.ALK 抑制逃逸：克服耐药性的机制和策略。
Sci Transl Med. 2012 Feb 8;4(120):120ps2. doi: 10.1126/scitranslmed.3003728.
4
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.厄洛替尼对比标准化疗用于治疗欧洲晚期 EGFR 突变阳性非小细胞肺癌患者的一线治疗（EURTAC）：一项多中心、开放标签、随机、3 期临床试验。
Lancet Oncol. 2012 Mar;13(3):239-46. doi: 10.1016/S1470-2045(11)70393-X. Epub 2012 Jan 26.
5
Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.ALK 重排肺肿瘤获得性克唑替尼耐药的机制。
Sci Transl Med. 2012 Feb 8;4(120):120ra17. doi: 10.1126/scitranslmed.3003316. Epub 2012 Jan 25.
6
Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.ALK 基因重排非小细胞肺癌患者对克唑替尼耐药的机制。
Clin Cancer Res. 2012 Mar 1;18(5):1472-82. doi: 10.1158/1078-0432.CCR-11-2906. Epub 2012 Jan 10.
7
ROS1 rearrangements define a unique molecular class of lung cancers.ROS1 重排定义了一类独特的肺癌分子亚型。
J Clin Oncol. 2012 Mar 10;30(8):863-70. doi: 10.1200/JCO.2011.35.6345. Epub 2012 Jan 3.
8
Crizotinib and testing for ALK.克唑替尼和 ALK 检测。
J Natl Compr Canc Netw. 2011 Dec;9(12):1335-41. doi: 10.6004/jnccn.2011.0115.
9
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.克唑替尼治疗携带 ALK 基因重排的晚期非小细胞肺癌患者的总生存影响：一项回顾性分析。
Lancet Oncol. 2011 Oct;12(11):1004-12. doi: 10.1016/S1470-2045(11)70232-7. Epub 2011 Sep 18.
10
Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK).基于结构的克唑替尼（PF-02341066）药物设计，克唑替尼是一种有效的、选择性的间质上皮转化因子（c-MET）激酶和间变性淋巴瘤激酶（ALK）双重抑制剂。
J Med Chem. 2011 Sep 22;54(18):6342-63. doi: 10.1021/jm2007613. Epub 2011 Aug 18.
Zotero 插件